Promising New Treatments Offer Hope Against Pancreatic Cancer

Pancreatic cancer remains one of the deadliest forms of the disease, with five-year survival rates still below 10 percent. Recent experimental drugs, however, are showing significant gains in early trials. The KRAS inhibitor daraxonrasib doubled median survival time compared with standard chemotherapy. An antibody therapy called NP137 also extended life by about six months in a small study. In addition, mRNA-based vaccines are eliciting immune responses that may help long-term survivors. Researchers caution that these results are preliminary and focused on safety. Ongoing phase 3 trials and further studies will be needed to confirm effectiveness. Still, growing investment in pancreatic cancer research is driving breakthroughs not seen in decades.

Use The App To Win ₦1m

Stories are shared by community members. This article does not represent the official view of NaijaWorld — the author is solely responsible for its content.